Epstein-Barr virus–positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop
American Journal of Clinical Pathology · 11.07.2025 · 164 (1) · 46-64
DOI: 10.1093/ajcp/aqaf020 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, online erschienen am 07.07.2025. Verfasst von Leticia Quintanilla-Martinez und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center, Tuebingen, Germany. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Lymphoproliferative Disorders, Killer Cells, Natural, Lymphoma, Extranodal NK-T-Cell. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
Objectives
To summarize the conclusions of the 2023 Society for Hematopathology/European Association for Haematopathology workshop regarding Epstein-Barr virus (EBV)–positive T- and natural killer (NK)–cell lymphoproliferative disorders (LPDs).
Methods
There were 38 cases submitted to session 3 of the workshop.
Results
Cases included extranodal NK/T-cell lymphoma (ENKTCL), nasal type (n = 16), EBV+ T- and NK-cell LPDs in children (n = 12), primary nodal EBV+ T- and NK-cell lymphoma (n = 5), and other EBV+ T- and NK-cell LPDs (n = 5). The ENKTCL cases highlighted some unusual features like indolent behavior, small cell morphology, and T-cell phenotype, including cases with CD4 and CD30 expression. The differential diagnosis of ENKTCL was illustrated by 4 cases with other primary cutaneous lymphomas. The difficulty in the diagnosis of systemic chronic active EBV disease, its complications, and the sometimes elusive boundaries among the EBV+ LPDs in children are also discussed. The submitted cases also unveiled cases of EBV+ γδ T-cell leukemia/lymphoma not recognized under current classifications and cases of EBV+ CD8+ cytotoxic lymphomas associated with treatment for B-cell lymphomas. The need to have a low threshold to investigate the presence of EBV is highlighted.
Conclusions
The diagnosis of EBV+ T- and NK-cell LPDs is complex and requires a multiparameter approach incorporating clinical information and morphologic and molecular features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Pathology and Neuropathology, University Hospital Tuebingen and Comprehensive Cancer Center, Tuebingen, Germany.
- Department of Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.
- Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, United States.
ORCID-Profile: Leticia Quintanilla-Martinez
Zitieren
APA
Quintanilla-Martinez, L., Li, S., & Chadburn, A. (2025). Epstein-Barr virus–positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop. American Journal of Clinical Pathology, 164(1), 46-64. https://doi.org/10.1093/ajcp/aqaf020
Vancouver
Quintanilla-Martinez L, Li S, Chadburn A. Epstein-Barr virus–positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop. American Journal of Clinical Pathology. 2025;164(1):46-64. doi:10.1093/ajcp/aqaf020
BibTeX
@article{QuintanillaMartinez2025,
author = {Quintanilla-Martinez, Leticia and Li, Shaoying and Chadburn, Amy},
title = {Epstein-Barr virus–positive T- and NK-cell lymphoproliferative disorders: Report from the 2023 SH/EA4HP Lymphoma Workshop},
journal = {American Journal of Clinical Pathology},
year = {2025},
volume = {164},
number = {1},
pages = {46--64},
doi = {10.1093/ajcp/aqaf020}
}
EUVIMED